Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 1 clinical study titled A Phase 1 Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088. The study aims to evaluate the safety, tolerability, and pharmacokinetics of ABBV-1088 in healthy adults, including Western, Han-Chinese, and Japanese participants. It also examines the drug-drug interaction between ABBV-1088 and itraconazole in Western participants, which is crucial for understanding the compound’s potential in diverse populations.
The study tests ABBV-1088, an oral capsule, across multiple doses and in combination with itraconazole. The intervention’s primary goal is to assess its pharmacokinetic profile and interactions, providing foundational data for further development.
The study employs a randomized, parallel assignment model with triple masking to ensure unbiased results. Its primary purpose is basic science, focusing on understanding the drug’s behavior in the body.
Key dates for the study include its start on August 28, 2024, with the latest update on September 9, 2025. The study is currently suspended, which is significant for stakeholders tracking its progress and potential market entry.
The suspension of this study may impact AbbVie’s stock performance and investor sentiment, as delays in clinical trials can affect projected timelines for drug approval and market entry. Competitors in the pharmaceutical industry may gain a temporary advantage, depending on their pipeline progress and market strategies.
The study remains ongoing, with further details available on the ClinicalTrials portal.